Prothena Corporation plc: Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update VITAL study 9-month results expected to be presented at a medical conference in 2021 Prasinezumab Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference PRX004 PRX005 IND expected by 3Q 2021 $80 million potential payment from Bristol Myers Squibb upon exercising their US license option in 2021 PRX012, a potential treatment for Alzheimer's disease, is a high affinity monoclonal antibody targeting a key epitope within the N-terminus of Aß IND expected by 1Q 2022 Upcoming Investor Conferences Members of the senior management team will present and participate in investor meetings at the following upcoming investor conferences: